Skip to main content
padlock icon - secure page this page is secure

Dermatologic Effects of Psychopharmacologic Agents in the Pediatric Population

Buy Article:

$68.00 + tax (Refund Policy)

Background: Many of the adverse effects of psychopharmacologic agents are dermatologic in nature, ranging from relatively benign rashes to severe, potentially lifethreatening conditions. For the pediatric population, many case reports describe cutaneous reactions, however large-scale studies in the pediatric population are nonexistent.

Objective: To review common dermatologic reactions to psychopharmacologic agents in pediatric population.

Method: Narrative review of current literature using PubMed database was conducted.

Results: Adverse cutaneous reactions that have been reported for these drugs include exanthematous rash, urticaria, lichenoid drug eruption, livedo reticularis, vitiligo, drug-induced hypersensitivity syndrome, drug reaction with eosinophilia and systemic symptoms syndrome, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.

Conclusion: Many of the serious conditions are rare but likely under-diagnosed in the pediatric population, despite being particularly vulnerable to certain agents. Specific risk factors unique to the pediatric population, such as differential drug metabolism compared to adults, must be considered in the management of psychotropic medications. This should influence the pediatrician's judicious use of psychotropic agents to ensure maximal safety and efficacy for their patients.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Rash; allergic reaction; dermatologic; drug reaction; pediatric; psychopharmacology; psychotropic

Document Type: Review Article

Publication date: April 1, 2018

More about this publication?
  • Current Psychopharmacology publishes peer-reviewed expert review articles and single topic guest edited issues on all aspects of pre-clinical and clinical research in psychopharmacology. The journal aims to be the leading forum for expert review articles in the field. The journal also accepts high-level original research articles on outstanding topics of preclinical and clinical psychopharmacology. Data must be published for the first time in Current Psychopharmacology.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more